and quarter Jan, you, everyone, joining business third Thank you, our for call. today us thank update for
regulation exploiting DNA drugs improve the to We cancer control overcome translator damage of discover cancer cycle will response into Cyclacel and resistance approached transcription biology pathways medicines patients. at the that to of Our or understanding is this by that novel vision treatments. life cell
medicines stockholder cost and business is by innovative their safety, pipeline and to develop value effectiveness. efficacy, demonstrating realize strategy of Our a
cyclindependent discovered pXX, his cancer. discovery malfunctions two-thirds David authority gene suppressor cell a Sir regulation programs drug who discovery key concentrated or that pathway. cancer Lane, resulted people our our started inhibitor. and founding key with advancing and components our in our in Under in with into work cycle transcription pXX guidance, CDKX/X a drug clinic CDKX/X global in drug inhibitor the CYCXXX These tumor isoforms, biology, kinase operate program principally Cyclacel’s with about efforts in as scientist, Professor of on lead which the novel of particular
CYCXXX cancer survive a race treatments. resistance suppression The and cells in ongoing has communities suppress suppressing ultimately Bcl-X and pro-survival normal Mcl-X cells Mcl-X works a by Mcl-X. and cancer of member family. surgical to scientific strategy confer a therapy, from is of a attracted onto cancer Bcl-X protein the help market to competitive the drugs gain proteins that advantage bring lot and to of attention a
demonstrated durable lung gynecological leader doses potentially Several a patients that protocols human Designing findings CYCXXX certain and amplification. suppression a cancers therapeutic or believe by is race tumors. leukemias in cancers at has certain to as Mcl-X Cyclacel this this monotherapy high including patients are overexpression Mcl-X We in tolerable is characterized with and strategy. as important solid of Mcl-X exploit in
CYCXXX milligrams Phase every enrolled X were of three four-hour a CYCXXX-XX These in single our patients was square intravenous dose the of in as of recommended per one Mcl-X Phase as previously the administration given part X observed reported majority in XXX study results weeks. which meter
intravenous as two or been in in the have three enrolling the one first is CYCXXX days first cycle. of hour for two administrations a two weeks four patients which We since part out given week
milligrams dose. fourth the reached flat has escalation XXX Dose at level
the XX%. assessment previously After that amplification response has The shrinkage PR Mcl-X achieved achieved a by PR report excited a investigator of was are four milligrams. patient or XXX cycles endometrial of at partial CYCXXX on and to treated with first CYCXXX We shrinkage stable cancer patient after tumor at with also A based with achieved stable XXX disease of with E milligrams investigator cycles, ovarian second of of cancer disease with XX%. shrinkage tumor amplification XX% the achieved tumor assessment. cycles treated patient for two two and Cyclin
shortly first Subject the part scams, Mcl-X. of that CYCXXX by with one parts such two, and a an follow-up study oral updated treated the confirmation safety we year this and form. PK first dose. suggests strategy We oral frequent data pharmacokinetic this dosing to as safety of be intravenously oral preferred with administered CYCXXX efficacy good patient, parallel, the initial at to have In patients XX data expect three began to the and data of next mechanistic finding and plan dosage in data schedule a IV milligrams may bioavailability. for transcripts formulation and Based from form preclinical suppress of we for on flat report
Venetoclax, data Preclinical combination or for now Bcl-X great by Mcl-X have CLL, Bcl-X. to us either line potential particular, studies Let both antibody. CYCXXX for with with demonstrated second patients suppressing strategies of synergy inhibitor the advanced is scientists an have with In preclinical in first approved data scientists anti-CDXX approved an turn first combination Cyclacel hematological venetoclax. in important alone and therapeutic or external demonstrated malignancies. and CYCXXX
Venetoclax Mcl-X and first granted hypomethylating line with or chemotherapy in combination AML FDA agent correlated eventually for is patients with amplification. this approval analog. nucleoside an in stop often recently, unfit treated accelerated More venetoclax for responding
where suppressing open relapsed the patients studies Bcl-X that’s result specifically relapsed and test AML and in or CYCXXX the and We against to have in offices CLL with dose of with clinical or in relapsed evaluating to MDS study. help CYCXXX-XX the patients study in refractory anti-tumor refractory activity CYCXXX-XX therefore to can both Mcl-X escalation or refractory or in leukemias, venetoclax combination
stop two have of for venetoclax, study CYCXXX treated CLL Both and ibrutinib cycles with CYCXXX-XX slow far. which six has cause CLL. attractive respectively eventual and achieving with combination is a cure venetoclax the In lymph In four therapy lymph or responding a patients relapse. received in and tolerated. node to relapsed venetoclax was enrollment toward with so Eradicating been failed refractory CYCXXX of combination treatment by and well for strategy a CLL leukemia the disease therefore nodes cells and an
Lymph provide may combination radiographic shrinkage CLL patients the meter the square. lymph venetoclax imaging and of Both important dosed of scan assessment every combination. had milligrams on nodes clues of by the XX large value the once at node CT on per CYCXXX two weeks by
of persist CYCXXX-XX doing According is eventually on for without the frontline CLL investigators, patient opened They patients open is additional are with slow the strategy study the has our large relapse. very In to implement to to enrollment others sites is in discussions. certain U.S. and Two the arise. amendments been will need Cyclacel enrollment. these sites and medical view are at been advised and increase with facts, have relapse that new well regimens CLL unmet protocol reason
the AML, MDS. Meanwhile, safety refractory recent in dose approval, better. study, increase magnitude the the including has an based we of been from possibility exploring unmet information developments enrolling AML our are relapsed AML escalation and both to medical remains Despite venetoclax in on XXX-XX, which need
combination CYCXXX milligrams have patients in every now weeks per with treated in venetoclax. once squared to XXX escalated dosed and eight have meter of two XXX-XX We
preclinical plays suppression either dominant in Unlike in AML, and beneficial both CLL, evidence hits The respectively, study synergy inducing expression double main alone. Bcl-X Mcl-X apoptosis Mcl-X rationale over venetoclax role. CYCXXX the than feature where confirming a Bcl-X by that and maybe suggesting this is suppressing for is more of of a protein supported
in Congress XXXX. with peripheral study effectiveness the an our We CYCXXX second XXX-XX of oral The Phase refractory nucleoside the sapacitabine in in program, combination and are combination patients with Bcl-X the of at reports X/X relapsed reaching the our this anticipated supports of In inhibitors AML first of investigator the patients AML. we blood combination with clinical MTD encouraged MDS XXth enrolling and data in by with of treated decreasing of part are safety two analogue, venetoclax. Hematology We in a European blast or published venetoclax. or study evaluating from sapacitabine, Association
or with that effective oral combination venetoclax investigations, regimen therefore, an to for AML front-line failed front-line clinical with prior in or agents. approved. is cytarabine, on agents prior is remissions sapacitabine in Venetoclax is cytarabine are who such approval offer of refractory or therapy, complete relapsed hypomethylating accelerated induces treatment as Based and which has AML, as and active may, administered. intravenously MDS have patients therapy, already therapy both venetoclax Combining hypomethylating in where sapacitabine
house. our In polo-like or in PLKX our clinical advanced human CYCXXX, leukemias with study. kinase to dose a patients inhibitor, third Three like XXX-XX, program, or have escalation recruited which in been discovered first single-agent we’re CYCXXX evaluating
xenograft evaluating patients and MD these demonstrated sponsor target Anderson models Center PLKX remains sale of years all the with potent Anderson three far. of first studies, dose candidates limited CYCXXX terms exchange is CYCXXX-XX three inhibition for XXX-XX, a high activity milestone human alliance, are malignancies. for and patient objective CYCXXX-XX, our toxicities Under indications in started that observed payments up Cyclacel MD part XXX-XX the been the All small patients inhibitor Cyclacel assumes over hematological the alliance cancers. to strategic with with studies. thus selective of on or and has four up have in for of of XXX Cancer molecule Alliance. a in costs in selective for No commercial
strategy. our to turn now us Let response DNA damage
mutations inherited the standard including DNA novel certain enhance for of control BRCA duration with efficacy goal clinical pathways, benefit mutations. to PARP survival. inhibitors, in with homologous of for or used modest The in those improve such standard care Our gynecological of BRCA and a recombination damage extend approved combination which of mutations, to HR-deficient by suggests need drugs to cancers, targeting disease here as the care include those cancers, is
still relevant durable HR-deficient after cancer, action PARP including from in works years. Sapacitabine has inhibitors. than an activity mechanism is of remission of a Sapacitabine in demonstrated by that patient six distinct BRCA-positive more mechanism the breast
leading trial and the data with BRCA-mutant sapacitabine ovarian cancer. Dana-Farber PARP rationale clinical sapacitabine ongoing Cancer are enrolling AACR cancer. breast approved is breast for sapacitabine an the olaparib Cyclacel supplying patients at This reported IST investigator-sponsored and Cancer inhibitor by sponsor and for the and is naïve or of inhibitor the with at Department and AstraZeneca Breast the provides XXXX of respectively. IST Institute olaparib, orally dosed PARP Recent
patient PR. has According total response the the cancer, five of to patients achieved partial and breast treatments. on or treated one patients are Three have a continuing BRCA-mutant been with investigators,
as and leadership We suppression with achievements in proud established company’s of have Mcl-X CYCXXX. in XXXX, are the especially position we
further provide We upcoming and progress XXX-XX sapacitabine ASH will AML/MDS at in of study. CLL our highlights presentations CYCXXX two for program the and with one our lead for our Conference
frequent efficacy and with relapsed our on relapsed XX months efficacy venetoclax clinical safety sapacitabine MDS. schedule PK next relapsed or patients Phase oral venetoclax milestones formulation the from in solid our and in CYCXXX safety executing Phase of And Phase X refractory we X Phase X reporting study for X and CYCXXX Phase AML or advancing refractory and data development or and As include for refractory safety AML the PK And CYCXXX Phase CYCXXX. Initial continue venetoclax relapsed first dosing of CLL strategy the key human data with CYCXXX and cancer. the Initial study in our programs, updated in study in advanced refractory the X/X an in patients data MDS. leukemias. X with the or study of
of and we our sapacitabine and have key of capital from the trial investigators the us patients. pathway BRCA-mutant hand, determining metastatic end cancer, when sapacitabine, olaparib in data the updated on through Also clinical to until XXXX, clinical in patients take with resources ongoing studies. by combination Xb/X AML estimated the elderly milestones With regulatory reported in submissibility breast of Phase the IST
now like turn to to I XXXX financials. review third our call to would the Paul? Paul quarter over
